PT1364959E - Cristal de derivado nucleosídeo de piridina - Google Patents

Cristal de derivado nucleosídeo de piridina Download PDF

Info

Publication number
PT1364959E
PT1364959E PT02711347T PT02711347T PT1364959E PT 1364959 E PT1364959 E PT 1364959E PT 02711347 T PT02711347 T PT 02711347T PT 02711347 T PT02711347 T PT 02711347T PT 1364959 E PT1364959 E PT 1364959E
Authority
PT
Portugal
Prior art keywords
compound
crystalline form
formula
angstroms
crystal
Prior art date
Application number
PT02711347T
Other languages
English (en)
Portuguese (pt)
Inventor
Takashi Takita
Keiichi Ohtsuka
Eiji Numagami
Susumu Harashima
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of PT1364959E publication Critical patent/PT1364959E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT02711347T 2001-02-09 2002-02-06 Cristal de derivado nucleosídeo de piridina PT1364959E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001033128 2001-02-09

Publications (1)

Publication Number Publication Date
PT1364959E true PT1364959E (pt) 2007-07-23

Family

ID=18896929

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02711347T PT1364959E (pt) 2001-02-09 2002-02-06 Cristal de derivado nucleosídeo de piridina

Country Status (21)

Country Link
EP (1) EP1364959B1 (cg-RX-API-DMAC7.html)
JP (2) JP3748536B2 (cg-RX-API-DMAC7.html)
KR (1) KR100679904B1 (cg-RX-API-DMAC7.html)
CN (1) CN100408591C (cg-RX-API-DMAC7.html)
AT (1) ATE361929T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002230164B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0207102A8 (cg-RX-API-DMAC7.html)
CA (1) CA2437994C (cg-RX-API-DMAC7.html)
CY (1) CY1106685T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303241B6 (cg-RX-API-DMAC7.html)
DE (1) DE60220024T2 (cg-RX-API-DMAC7.html)
DK (1) DK1364959T3 (cg-RX-API-DMAC7.html)
ES (1) ES2286237T3 (cg-RX-API-DMAC7.html)
HU (1) HU229294B1 (cg-RX-API-DMAC7.html)
IL (2) IL157216A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007123A (cg-RX-API-DMAC7.html)
NZ (1) NZ527393A (cg-RX-API-DMAC7.html)
PT (1) PT1364959E (cg-RX-API-DMAC7.html)
RU (1) RU2256666C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002064609A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200306121B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081419B1 (en) 1999-09-02 2013-08-07 Ibiden Co., Ltd. Printed circuit board and method of manufacturing printed circuit board
CN101232776B (zh) 1999-09-02 2011-04-20 揖斐电株式会社 印刷布线板
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
PL2307002T3 (pl) 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
PL2696878T3 (pl) 2011-04-14 2020-01-31 Cyclacel Limited Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
FI105556B (fi) * 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta

Also Published As

Publication number Publication date
HUP0303159A3 (en) 2007-06-28
AU2002230164B2 (en) 2005-04-07
HUP0303159A2 (hu) 2003-12-29
BRPI0207102A8 (pt) 2018-02-27
KR100679904B1 (ko) 2007-02-07
CA2437994C (en) 2011-05-17
WO2002064609A1 (en) 2002-08-22
CZ20032111A3 (cs) 2003-12-17
CN1501939A (zh) 2004-06-02
KR20030081424A (ko) 2003-10-17
IL157216A0 (en) 2004-02-19
ES2286237T3 (es) 2007-12-01
CY1106685T1 (el) 2012-05-23
HU229294B1 (en) 2013-10-28
EP1364959B1 (en) 2007-05-09
ZA200306121B (en) 2005-01-26
CA2437994A1 (en) 2002-08-22
DK1364959T3 (da) 2007-06-04
EP1364959A1 (en) 2003-11-26
NZ527393A (en) 2004-07-30
RU2256666C2 (ru) 2005-07-20
ATE361929T1 (de) 2007-06-15
BR0207102A (pt) 2004-01-27
JP4356998B2 (ja) 2009-11-04
DE60220024T2 (de) 2007-11-22
JP2006008699A (ja) 2006-01-12
EP1364959A4 (en) 2004-03-24
CN100408591C (zh) 2008-08-06
IL157216A (en) 2008-03-20
MXPA03007123A (es) 2003-11-18
JP2002308895A (ja) 2002-10-23
JP3748536B2 (ja) 2006-02-22
RU2003124648A (ru) 2005-02-27
DE60220024D1 (en) 2007-06-21
CZ303241B6 (cs) 2012-06-13

Similar Documents

Publication Publication Date Title
BR112020022738A2 (pt) formas cristalinas de um inibidor tlr7/tlr8
US20090181990A1 (en) Stable amorphous form of pemetrexed disodium
PT1541146E (pt) Solvato de hemitartarato de zolpidem
ES3034771T3 (en) Solid state forms of sugammadex sodium
ES2286237T3 (es) Cristales de un derivado nucleosido de pirimidina.
US6908906B2 (en) Crystalline forms of pyrimidine nucleoside derivative
WO2024248083A1 (ja) キノリン置換化合物の結晶
ES2228848T3 (es) Formas hidratadas y cristalinas de un compuesto de acido neuraminico.
RU2476440C2 (ru) Кристаллические формы мононатриевой соли d-изоглутамил-d-триптофана
EP3867264A1 (en) Solid state forms of voclosporin
AU2005223728A1 (en) Azabicyclooctan-3-one derivatives and use thereof
CN113788826B (zh) 共晶体
ES2984584T3 (es) Formas cristalinas de un inhibidor de LTA4H
JP3920041B2 (ja) ノイラミン酸化合物の水和物及び結晶
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
WO2026095022A1 (ja) キノリン置換化合物の結晶
JP4424644B2 (ja) ノイラミン酸化合物を含有する医薬
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
JP2007297332A (ja) ベンズアミジン誘導体の結晶
BR112017008903B1 (pt) Formas cristalinas de maltol férrico